Weight Loss Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in ObesityBy adminApril 1, 20220 Altimmune, IncWe also announced that we have completed enrollment for a 12-week phase 1b study of pembijutide in subjects with…
